☆ 4.5 Letter

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

BLOOD CANCER JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Curtis A. Lachowiez et al.

Summary: The safety and efficacy of combining the IDH1 inhibitor ivosidenib with the BCL2 inhibitor venetoclax, with or without azacitidine, were evaluated in patients with IDH1-mutated myeloid malignancies. The combination therapy showed promising results with high response rate and manageable adverse events.

BLOOD CANCER DISCOVERY (2023)

Add to Collection

Article Oncology

Impact of Venetoclax and Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Daniel A. Pollyea et al.

Summary: The combination therapy of venetoclax and azacitidine shows high efficacy and safety in patients with IDH1/2-mutant acute myeloid leukemia (AML), leading to improved overall survival.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Medicine, General & Internal

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

C. D. DiNardo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Hematology

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Doehner et al.

BLOOD (2017)

Add to Collection

Article Oncology

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva et al.

CANCER DISCOVERY (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

Steven M. Chan et al.

NATURE MEDICINE (2015)

Add to Collection

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Related references

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Impact of Venetoclax and Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

Export Citation

Share Paper